Egis Pharmaceuticals PLC

Egis Pharmaceuticals PLC

Featured Exhibitors

Information

Egis is a leading Hungarian generic pharmaceutical company with over 110 years of experience. In 2024/2025 financial year, Egis Group generated net sales of EUR 773 million. We cover the full value chain—from R&D and API/FP manufacturing to marketing in 60+ countries. At Egis, besides simple generics, we deliver value-added generic and highly potent products through advanced chemistry, streamlined production, and strong IP expertise. Our portfolio includes 656 products focused on cardiovascular, CNS, diabetes, dermatology, oncology and wound care.
Exhibitor Type
Featured Exhibitor
Organization Type
Manufacturer/Innovator
Country/Region
Hungary
Zone
Integrated Pharma
Markets Active In
North America (USA, Canada)Middle East Region (e.g. UAE)Central America (e.g. Mexico)East Asia (e.g. China, Japan, Korea)Europe - EU countriesEurope - non EU (e.g. UK, Russia, ex-CIS countries)South America (e.g. Brazil, Colombia)South Asia (e.g. India, Pakistan, Sri Lanka)South East Asia (e.g. Thailand, Philippines, Singapore)
Products and Services
Finished Dosage Forms (Products)Contract Development and Manufacturing Organisations (CDMOs) and Contract Manufacturing Organisations (CMOs) (Services)
Product Types
Finished Dosage Forms (Products)
Service Types
Contract Development and Manufacturing Organisations (CDMOs) and Contract Manufacturing Organisations (CMOs) (Services)
Product Categories
  • Finished Dosage Forms
    • Out-licensing

    Social media

    Contact details

    https://www.egis.health
    Hungary

    Sessions

    Value Added Medicines and Differentiated Generics

    Tuesday, October 6, 2026 1:45 PM to 2:10 PM
    Global Pharma Outlook: Hall 7 - 7H81
    Miquel MARTI · Egis Pharmaceuticals PLC